iTeos Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
iTeos Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • iTeos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$7.13M, a 79.2% increase year-over-year.
  • iTeos Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$108M, a 281% decline year-over-year.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$113M, a 217% decline from 2022.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $96.7M, a 54.9% decline from 2021.
  • iTeos Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $215M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$113M -$209M -217% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 $96.7M -$118M -54.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 $215M +$253M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 -$38M -$15.6M -69.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-23
2019 -$22.5M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.